Opiant Pharmaceuticals (Opiant Pharmaceuticals) Price-to-Tangible-Book : 5.21 (As of May. 13, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Opiant Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-05-13), Opiant Pharmaceuticals's share price is $20.65. Opiant Pharmaceuticals's Tangible Book per Share of Sep. 2022 for the quarter that ended in Sep. 2022 was $3.97. Hence, Opiant Pharmaceuticals's Price to Tangible Book Ratio of today is 5.21.

The historical rank and industry rank for Opiant Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

OPNT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.9 Med: 2.71 Max: 2742.14
Current: 5.2

During the past 13 years, Opiant Pharmaceuticals's highest Price to Tangible Book Ratio was 2742.14. The lowest was 0.90. And the median was 2.71.

OPNT's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.71 vs OPNT: 5.20

A closely related ratio is called PB Ratio. As of today, Opiant Pharmaceuticals's share price is $20.65. Opiant Pharmaceuticals's Book Value per Sharefor the quarter that ended in Sep. 2022 was $3.97. Hence, Opiant Pharmaceuticals's P/B Ratio of today is 5.20.

Opiant Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Opiant Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals Price-to-Tangible-Book Chart

Opiant Pharmaceuticals Annual Data

Trend

Jul12

Jul13

Jul14

Jul15

Jul16

Jul17

Dec18

Dec19

Dec20

Dec21

Price-to-Tangible-Book

Get a 7-Day Free Trial

6.10

3.30

1.75

0.96

3.53

Opiant Pharmaceuticals Quarterly Data
	Oct17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Price-to-Tangible-Book	Get a 7-Day Free Trial															2.83	3.53	2.77	2.08	2.71

Competitive Comparison of Opiant Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Opiant Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opiant Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's Price-to-Tangible-Book falls into.

Opiant Pharmaceuticals Price-to-Tangible-Book Calculation

Opiant Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Sep. 2022 )
	=	20.65	/	3.967
	=	5.21

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Opiant Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Opiant Pharmaceuticals (Opiant Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opiant Pharmaceuticals Inc (NAS:OPNT) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401

Website

https://www.opiant.com

Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.

Executives

David D O'toole	officer: Chief Financial Officer	1640 MARENGO STREET, LOS ANGELES CA 90033
Ellison Mark Jason Heath	other: UK Managing Director	C/O OPIANT PHARMACEUTICALS, INC., 201 SANTA MONICA BLVD., SUITE 500, SANTA MONICA CA 90401
Roger Crystal	director, 10 percent owner, officer: Chief Executive Officer	445 PARK AVE, 10TH FL., NEW YORK NY 10022
Phil Skolnick	officer: Chief Scientific Officer	C/O DOV PHARMACEUTICAL, INC., 433 HACKENSACK AVENUE, HACKENSACK NJ 07601
Brian Gorman	other: General Counsel	233 WILSHIRE BLVD, SUITE 280, SANTA MONICA CA 90401
Matthew R. Ruth	officer: Chief Commercial Officer	233 WILSHIRE BLVD., SUITE 280, SANTA MONICA CA 90401
Michael Sinclair	director, 10 percent owner, officer: Executive Chairman	86 GLOUCESTER PLACE, LONDON XX W1U6HP
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Ann L. Macdougall	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Thomas T. Thomas	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Masuoka K. Lorianne	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Gabrielle Alison Silver	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Rahsaan Thompson	other: General Counsel	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Aziz Mottiwala	officer: Chief Commercial Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Richard J Daly	director	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134